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Abstract 
 
Background: Highly active antiretroviral therapy (HAART) treatments, particularly those comprising protease inhibitors have 
been demonstrated to cause, in a majority of  HIV-infected individuals, a metabolic syndrome (lipodystrophy/lipoatrophy, 
dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be correlated to with an augmented risk of cardiovascular 
disease. A cautious division in several groups of the cardiovascular risk of HIV infected people under HAART is required as 
said by the most current medical principles. Aim/methods: The aim of this review is to investigate the metabolic problems of 
treatments used to cure HIV infection. Results: They imply that HAART-linked lipodystrophy may be the outcome of adipocyte 
alteration engaging changeable mixtures of apoptosis, imperfect lipogenesis, and amplified metabolic action in diverse adipose 
body regions. In this survey, multivariate analysis made known that, between the inspected parameters, apo C-III was the 
single element powerfully connected with the incidence of lipodystrophy. Conclusion: Fat relocation may lead the progress of 
metabolic barriers in HIV-contaminated subjects getting HAART. The strictness of these metabolic deviations enhances with 
rising harshness of lipodystrophy, and they are related with an elevated threat of cardiovascular incidents: around 1.4 cardiac 
episodes per 1000 years of treatment regarding the Framingham result. Even if several surveys have revealed that the 
consume of glitazones for the cure of HIV-related lipodistrophy leads to an improvement in insulin resistance, contrasting 
results propose that additional labor is required . 
 
Keywords: Human immunodeficiency virus,  highly active antiretroviral therapy, nucleoside overturned transcriptase inhibitors, 
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1. Introduction 
 
The foreword of highly active antiretroviral treatment (HAART) has considerably adjusted the itinerary of human 
immunodeficiency virus (HIV) syndrome, with extended survival and enhanced quality of life in HIV-infected patients.  
Nevertheless, HAART treatments, principally those comprising protease inhibitors (PIs) have illustrated to cause in 
a greater part of HIV-infected subjects metabolic and physical alterations that in the common population are related to an 
amplified hazard of cardiovascular syndrome generating an interesting clinical outlook. 
The foreword of highly active antiretroviral therapy (HAART), HIV- linked morbidity and mortality have turned down 
and continued existence and life worth have developed considerably in HIV- infected subjects with access to HAART 
(Lohse N et al 2007; Sterne JA, Hernan MA 2005) 
HAART has altered a commonly lethal disease to a persistent, controllable communicable illness that entails 
enduring healing. Metabolic disease is an whole of central obesity and metabolic anomalies that presents an augmented 
threat of cardiovascular illness and type 2 diabetes (Tien PC et al 2007; NCEP 2002).  Regarding  preceding surveys, the 
occurrence of metabolic disease between HIV-infected subjects varies from 15.0 % to 43.2% (Jerico C 2005; Samaras K, 
E-ISSN 2281-4612 
ISSN 2281-3993        
Academic Journal of Interdisciplinary Studies
MCSER Publishing, Rome-Italy 
                                   Vol 4 No 1 
                            March 2015 
 
 154
Wand H 2007). 
The dissimilarities in prevalence of metabolic disease amid the published surveys may be elucidated by the 
dissimilar survey populations and standards used and diverse inhabitants revised (Mondy K 2007; Sobieszczyk ME, 
Hoover DR 2008).   
Whereas, the affiliation among metabolic disease and HAART is recognized, (Hoover DR 2008) the association 
amid every individual antiretroviral tool with metabolic  disease  is hard to describe since as a minimum two categories of 
antiretroviral instruments are concomitantly begun.  
Nevertheless, it has been stated that the application of protease inhibitors (PIs) have to be correlated with 
metabolic syndrome (Samaras K 2007;Jacobson DL, Tang 2006).  Of all nucleoside reverse transcriptase inhibitors 
(NRTIs), stavudine is the most commonly cited antiretroviral agent that is associated with metabolic syndrome (Jerico C 
2005; Hansen BR, Petersen J 2009). 
 
2. Methodology 
 
The aim of this review is to investigate the metabolic problems of treatments used to cure HIV infection. 
The progress of HAART-related metabolic disorder is multifaceted and a quantity of features are engaged, 
incorporating straight consequences of HAART on lipid metabolism, endothelial and adipocyte cell role, and 
mitochondria. 
PIs target the catalytic region of HIV-1 protease. This region is homologous with regions of two human proteins 
that regulate lipid metabolism: cytoplasmic retinoic-acid binding protein-1 (CRABP-1) and low density lipoproteinreceptor- 
related protein (LRP) ( Carr A et al  1998; Carr A, Samaras K, Chisholm DJ 1998). 
It has been hypothesized, although without strong experimental support, that this homology may allow PIs to 
interfere with these proteins, which may be the cause of the metabolic and somatic alterations that develop in PIs-treated 
patients (Carr A et al  1998; Carr A, Samaras K, Chisholm DJ 1998). 
The reticence enhances the speed of apoptosis of adipocytes and decreases the rate at which pre-adipocytes 
separate into adipocytes, with the ultimate outcome of diminishing triglyceride storage and augmenting lipid liberation. 
PIs-combination to LRP would harm hepatic chylomicron uptake and endothelial triglyceride clearance, generating 
hyperlipidemia and insulin resistance (Carr A et al  1998; Carr A, Samaras K, Chisholm DJ 1998). 
Ultra structural investigation of adipocytes in PI- stimulated lipodystrophy exposes changes comprising distraction 
of cell membranes, divided cytoplasmic edges, irregular cell charts, and lastly fat droplets resting liberated in the 
connective tissue, with macrophages between them. Numerous adipocytes demonstrate variable division of fat globules 
with decline in cell dimensions and plentiful, mitochondria-affluent cytoplasm.  
These results imply that HAART-linked lipodystrophy may be the outcome of adipocyte alteration engaging 
changeable mixtures of apoptosis, imperfect lipogenesis, and amplified metabolic action in diverse adipose body regions 
(Carr A, Samaras K, Chisholm DJ 1998). 
Vernochet et al. appraised the consequence of six different PIs on the segregation of cells from three clone lines. It 
was investigated the ability of ritonavir  to be found mutually into drug-susceptible and drug-resistant cultivated 
adipocytes (Vernochet C et al 2003).  
The authors utilized a susceptible ELISA to establish intracellular concentration of ritonavir from 3T3- L1 and 
Ob1771 preadipocytes. Nelfinavir and lopinavir restrained adipocyte differentiation while amprenavir was useless. 
Indinavir, saquinavir and ritonavir restrained differentiation of 3T3-L1 and 3T3-F442A cells but did not modify 
differentiation of each Ob1771 or embryonic stem cells. The investigators illustrated that ritonavir gathered in 
preadipocytes and completely distinguished 3T3-L1 adipocytes as a role of its outside a cell concentration (Vernochet C 
et al 2003).  
Regarding the outcomes of this experimental study  PIs restrain adipocyte differentiation stipulating the cell pattern 
used. Ritonavir appears to build up into preadipocytes and adipocytes, implying a straight result on within cell targets. 
Conversely, within cell gathering was obviously not adequate as Ob1771 cells were resistant to the delayed result 
of ritonavir (Vernochet C et al 2003). 
Several records point out that PIs-related dyslipidemia may be partially the origin, either by PIs-interceded 
reservation of proteasome action and gathering of the dynamic section of sterol rigid element-requisite protein (SREBP)-
1c in liver cells and adipocytes in HIV-infected subjects (Fauvel J& Bonnet E 2001).  
In this survey, multivariate analysis made known that, between the inspected parameters, apo C-III was the single 
element powerfully connected with the incidence of lipodystrophy (Bonnet E & Ruidavets JB 2001).  
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The progression homologies have been illustrated among HIV protease and human site-1 protease (S1P) that 
stimulates SREBP-1c and SREBP-2 trails. 
This implies the presence of a genetic predisposition to hyperlipoproteinemia in PIs-treated patients (Caron M et al 
2003). There is also evidence that PIs directly inhibit the uptake of glucose in insulin-sensitive tissues, such as fat and 
skeletal muscle, by selectively inhibiting the glucose transporter Glut4(Murata H & Hruz PW 2000). 
The correlation among the level of insulin resistance and ranks of solvable type-2-TNF-alpha receptor 
recommends that an inciting spur may contribute to the progress of HIV-allied lipodystrophy (Mynarcik DC 2000). TNF 
alpha stimulates 11-beta-hydroxysteroid dehydrogenase type-1 that transfers static cortisone to active cortisol. The 
movement of this enzyme is more elevated in visceral fat in contrast to subcutaneous fat. Visceral fat can generate 
cortisol that might proceed within adipocytes and raise lipid gathering ( Gougeon ML & Penicaud L 2004). There is data 
for nucleoside-stimulated mitochondrial failure in HIV-infected subjects cured with nucleoside holding HAART since 
lipodystrophy with tangential fat dissipating is linked with a regression in subcutaneous fat storing tissue mitochondrial 
DNA substance (Depairon M et al 2001). This result has been particularly explained with the application of stavudine and 
was connected with the duration of revelation to this medicine (Seminari E & Tinelli C 2002).  
 
 
 
Fig 1. HAART-related fat relocation  syndrome. Buffalo hump and raised abdominal girth. Courtesy of A. W. Karchmer, C. 
Mantzoros, and S. Tsiodras. Leow et al. • Clinical Review J Clin Endocrinol Metab, May 2003, 88(5):1961–1976  
 
Adipocytes conceal a variety of adipocytokines which manage insulin sensitivity (Vigouroux C 2003). There are data that 
an adiponectin, a protein product of the apM1 gene, which is stated solely in adipocytes (Haque WA et al 2002), plays a 
role in development of  HIV-linked lipodystrophy. Animal and cross-sectional surveys in humans have revealed that 
adiponectin is inversely compared with aspects of this metabolic syndrome as well as obesity, insulin resistance, type 2 
diabetes, and coronary heart illness, as well as hereditary and acquired lipodystrophies in non-HIV contaminated 
subjects. This disorder has lately been associated to a quantitative locus on chromosome 3q27, the setting of the apM1 
gene (Carr A, Samaras K; Burton S 1998). 
Adiponectin was considerably connected with triglycerides, abdominal visceral fat, insulin resistance and high 
concentration lipoprotein (HDL) cholesterol stages by means of bivariate analysis.  
In a study of 112 HIV-infected subjects getting HAART, (Carr A, Samaras K; Burton S 1998) the alliance of 
adiponectin with insulin resistance turned into non important after altering for NRTIs aplication, telling that alterations in 
adiponectin stages may lie beneath the deterioration result of NRTIs use on insulin resistance.  
The insulin sensitivity was linked completely with adiponectin and unconstructively with leptin and interleukin- 6 
(Vigouroux C 2003) in a assessment of 131 successive HIV-infected males under PIs-based HAART .  
Parallel effects have been described moreover in a cross-sectional study by Kosmiski et al. (Kosmiski L, Kuritzkes 
D 2003) where adiponectin levels were notably and positively connected with insuline vulnerability after modification for 
fat gathering and adiponectin rank was an autonomous indicator of insuline sensitivity (Kosmiski L, Kuritzkes D 2003). 
 
E-ISSN 2281-4612 
ISSN 2281-3993        
Academic Journal of Interdisciplinary Studies
MCSER Publishing, Rome-Italy 
                                   Vol 4 No 1 
                            March 2015 
 
 156
 
 
Fig. (2). Prevalence of the main medical and laboratory results inspected in HIV-infected subjects after the preface of  
HAART compare d to the pre-HAART phase. 
 
3. Results 
 
The occurrence of the main clinical and laboratory conclusions noted in HIV-infected subjects later than the foreword of 
HAART contrasted to the pre-HAART stage is observed in Fig. 1.  
Fat relocation. HIV-allied lipodystrophy undescribed prior to the preface of HAART, was first illustrated in 1998 
(Carr A et al 1998). It is distinguished by the existence of a dorso-cervical fat filling enhanced abdominal restraint and 
breast dimension, lip atrophy of subcutaneous fat of the visage, buttocks and limbs, and distinction of veins on the 
extremities.  
The usual occurrence of one corporeal deviation is thought to be about 47 % in healthy HIV-infected subjects 
getting  HAART, although reported rates vary since 16% to 76% [Grinspoon S& Carr A 2005]. Changes in rates may be 
persuaded by age, gender, the sort and length of antiretroviral treatment, and the absence of a purpose and an 
authenticated case description (Grinspoon S& Carr A 2005).  
As in heritable lipodystrophy patterns (Garg A et al  2005), fat relocation may lead the progress of metabolic 
barriers in HIV-contaminated subjects getting HAART. The strictness of these metabolic deviations enhances with rising 
harshness of lipodystrophy, and they are related with an elevated threat of cardiovascular incidents: around 1.4 cardiac 
episodes per 1000 years of treatment regarding the Framingham result (Grinspoon S& Carr A 2005). There is no 
scientifically verified remedy for any trait of lipodystrophy [ Carr A & Samaras K 1998].  
Amplified serum total and low density lipoprotein (LDL) cholesterol and triglyceride ranks have been detected in 
nearly 70% of HIV-contaminated subjects with lipodystrophy (Carr A & Samaras K 1998).  
Regarding  lipodystrophy, an alternative in the handling of dyslipidemia in subjects  getting PIs-counting HAART is 
to manage a mixture treatment without PIs [Carr A, Hudson J 2001; Clumeck N  2001]. Atazanavir, a novel azapeptide PI, 
appears  not to be linked with important dyslipidaemia and insulin resistance as noticed with other PIs (Piliero PJ et al 
2002). The outcomes of a stage 2 randomized test that evaluated lipid modifications after 32 weeks of treatment with 
atazanavir with those with nelfinavir  (both in group with stavudine and lamivudine) demonstrated that ranks of total 
cholesterol and LDL cholesterol augmented extensively more between patients who applied  nelfinavir (+21 % and +26 
%, correspondingly) than amid those who used atazanavir (+4% and +1%, respectively) (Grover SA & Coupal L 2005).  
Consistent with a recent study, lipid outline gets better by substituting PIs with efavirenz, nevirapine or abacavir 
with more distinct effects in non-lipodystrophic subjects. On the contrary, this approach does not look like to be valuable 
for repealing body fat deformities (Fisac C & Fumero E 2005). In relation to another study the efavirenz-persuaded 
enhance in HDL-cholesterol is manipulated by the resistance gene 1 C3435T polymorphism (Alonso-Villaverde C 2005). 
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Fig 3. Abdominal CT scan illustrating  hepatomegaly in a subject with HAART-linked  lipodystrophy. Courtesy of  Beth 
Israel Deaconess Medical Center (Boston, MA). 
 
It has been noticed in 7% to 12 % of the individuals with lipodystrophy the appearance of insulin resistance and type 2 
diabetes mellitus (Carr A et al 2003). It is essential to memorize that various glitazones are by the CY3A4 trail, which 
could raise the danger of developing myositis and hepatitis if used concurrently with PIs.  
The predominance of hypertension in HIV illness has been projected to be about 18-24% before the preface of 
HAART (Aoun S & Ramos E. 2000). Hypertension is presently believed element of HAART-linked metabolic disorder 
[Gazzaruso C & Bruno R 2003]. It seems to be connected to PIs-stimulated  lipodystrophy and metabolic 
syndrome with an occurrence of up to 68 % in subjects with HAART-linked metabolic disorder (Gazzaruso C & 
Bruno R 2003; Sattler FR 2001). When curing hypertension in HIV-infected patients with HAART-allied metabolic 
disorder, it should be distinguished that beta-blockers and diuretics might exacerbate the metabolic outlines of these 
subjects.  
 
4. Conclusions and Recommendations 
 
Principles for the administration of dyslipidemias in the universal population, like those of the National Cholesterol 
Education Plan also stand for the origin for therapeutic recommendations in HIV infected persons, as defined by the HIV 
Medicine Alliance of the Infectious Disease Society of US  and by the Pavia Agreement Declaration (Volberding P et al 
2003). 
HAART treatment with didanosine plus stavudine appear to create a larger enhance in serum lactate and 
lipodystrophy than remedies derived from zidovudine plus lamivudine in the initial year of treatment (Depairon M & 
Chessex S 2001). Replacement of stavudine with abacavir or zidovudine advances mitochondrial indices and fat 
apoptosis in the location of lipoatrophy [McComsey GA 2005] 
Even if several surveys have revealed that the consume of glitazones for the cure of HIV-related lipodistrophy 
leads to an improvement in insulin resistance, contrasting results propose that additional labor is required (Carr A, 
Workman C & Carey D 2004). 
There are no communications among NRTIs and nucleotide reverse transcriptase inhibitors and anti-arrhythmics. 
Angiotensin-adapting enzyme inhibitors and angiotensin II-receptor blockers might be taken into account, but records 
from restricted clinical tests appraising these drugs in this division of patients are missing. 
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